Healio | Ocular Surgery News’ Post

Glioblastoma is a highly heterogeneous tumor whose pathophysiological complexities dictate both the diagnosis of disease severity as well as response to therapy. Conventional diagnostic tools and standard treatment regimens have only managed to achieve limited success in the management of patients suspected of glioblastoma. Extracellular vesicles (Exosomes) are an emerging liquid biopsy tool that has shown great promise in resolving the limitations presented by the heterogeneous nature of glioblastoma. Read more https://lnkd.in/eerPkJHE #Exosome #extracellularvesicles #kosheeka #biotech #research

Survival outcomes on CDK4/6 inhibitors from two trials - based on intrinsic subtypes https://lnkd.in/dsH5fT2e 2nd generation Genexpression tests can generate clinical insights.

Today, we're honouring a World Kidney Day, a crucial reminder of the impact of kidney disease worldwide. Gubra contributes to making a healthier society by aiding companies and research institutes in the development of more effective drugs for kidney diseases. Our comprehensive CRO services specialize in supporting preclinical drug development for chronic kidney disease (CKD), diabetic kidney disease (DKD), and acute kidney injury (AKI).   With our extensive range of preclinical models and cutting-edge technologies, including clinically relevant biomarkers, automated AI-based histology, and quantitative 3D whole-kidney imaging, we enable accurate, objective, and comprehensive analysis of drug treatment effects on renal outcomes.   Interested in learning about how we can support your kidney research? Read about our CRO services here: https://lnkd.in/e4macggE #worldkidneyday #kidneyhealthforall #lifesciences

Insights into the application of #CARTcells in treating #MultipleMyeloma - a look at their potential, limitations & strategies employed to enhance their efficacy. Read more in this Nature paper: https://lnkd.in/ewAgXT5G #CancerResearch

Having become well-established in oncology, we at #C4XD believe that precision medicine approaches are on the cusp of delivering more effective therapies to patients suffering from a range of immunological and inflammatory conditions. As such we're excited to report that our PatientSeek genetics platform has been able to generate a genetics-only signature that separates responder and non-responders to the alpha4beta7 antibody vedolizumab used in the treatment of #IBD. We aim to use this signature in supporting clinical design for own small molecule alpha4beta7 program, as well as identifying predictive signatures to underpin the other programs in our portfolio, particularly our TNFalpha and PAD4 programs. #precisionmedicine

Today Food and Drug Administration approved the world’s first medicine based on CRISPR gene-editing technology, a groundbreaking treatment for sickle cell disease that delivers a potential cure for people born with the chronic and life-shortening blood disorder. This innovation is a step in the right direction, but comes with a need to risk stratify the patient without cultural and other biases. With this, the success of gene therapy in clinical practice depends not only on scientific safety and efficacy, but also on the cost to the patient ( financially, time to fulfill the treatment protocol, etc.) and strength of the trust between the sickle cell community (mostly black patients) and the health care system. Post-market surveillance, physician/patient education and of course insurance coverage will be factors to mitigate that will ultimately affect uptake of this new therapeutic treatment. #geneediting #sicklecell #biotech #healtdisparities

Nemo is here! The IL-31 started life at ZymoGenetics in 2004. If only we knew then what we know now. Donald Leung, Jon Hanifin, and I were invited to the ZymoGenetics offices in the fall of 2004 to opine on potential clinical indications of IL-31 or IL-31 antagonists based on an understanding of the ligand, the receptor, and the responses in IL-31 knock-out mice. We suggested #asthma might be a useful target. How silly we were! In our face was a phenomenal opportunity to explore #pruritus and pruritus associated inflammation. It happened but it took nearly two decades to get there. The results: #nemolizumab stops itch and improves signs of #atopicdermatitis with EASI-75 responses of 42% - 44% at week 16. It works. Patients I have in the study consistently reported early and almost complete resolution of purritus: “I have never felt better” being a common refrain. There is so much to explore with these results being just the beginning. Most of all, it is fantastic for patients to have another treatment option. #eczema #clinicaltrial #drugdevelopment

💛 ❤️ Patients are the key to finding new treatments for EHE. Researchers need tumor tissue from EHE patients to understand disease progression and speed the development of new drugs and therapies. If you have an upcoming procedure, please contact our Biobank team at biobank@fightehe.org.⁠ ⁠ Learn more⁠👇 🔗 https://lnkd.in/enQAjVP⁠ ⁠ #EHEbiobank #fightEHE #EHE #rarecancer #rareasone #raresarcoma #EHEfoundation #rarediseasedayofficial #sarcoma #raredisease #rarediseaseawareness #cancerawareness #science #patientpoweredresearch #patientsarethekey #legacydonation

Relapse Multiple Myeloma (MM) patients urgently need more effective therapies. Vrije Universiteit Amsterdam (VU Amsterdam) Takeda Molecular Templates publish a nice study on the development of a toxin body (CD38 scFv linked to Shiga-like toxin A) synthesized by ATUM. The toxin body its internalized and the Shiga-like toxin cause cell death to MM cells with minimal toxicity to non-MM cells. Toxin body also show efficient in-vivo activity in mouse xenograft models. https://lnkd.in/gvRw8Kab

Our CSO Peter Adamson discusses 'Diabetic Eye Disease - the urgent need for early, non-invasive treatments' in the Spring Issue of @Drug Discovery World.   Our groundbreaking oral drug #danegaptide, currently in a phase 1b/2a clinical trial, seeks to provide an alternative to the current invasive procedures involving laser to the macula, or injections of medicine, into or around the eye.   Read the full article here to learn more about why there is a need for better therapies to treat diabetic retinal disease, and the current progress in the field (page 26-28). https://bit.ly/499WN7w   #ophthalmology #maculardegeneration #diabeticretinopathy #DR #AMD #eyediseases #diabeticmacularedema